What is ADTRALZA 150mg/ml
ADTRALZA is a prescription medication containing tralokinumab, a human monoclonal antibody designed to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older who are candidates for systemic therapy. It is administered via subcutaneous injection and is available in pre-filled syringes containing 150 mg of the active ingredient.
How to use ADTRALZA 150mg/ml
Administration Guidelines:
Initial Dose: 600 mg, administered as four 150 mg subcutaneous injections at different sites on the same day.
Maintenance Dose: 300 mg every other week, given as two 150 mg injections.
Injection Sites: Thigh, abdomen (excluding the 5 cm area around the navel), or upper arm if administered by a caregiver.
Preparation: Allow the pre-filled syringe to reach room temperature for 30 minutes before injection.
Inspection: Ensure the solution is clear to opalescent and colorless to pale yellow, without visible particles.
Rotation: Rotate injection sites with each dose to prevent skin irritation.
Missed Dose:
If a dose is missed, administer it as soon as possible and then resume the regular dosing schedule.
Mode of Action ADTRALZA 150mg/ml
Tralokinumab, the active component of ADTRALZA, is a monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13), a cytokine involved in the inflammatory processes of atopic dermatitis.
Mechanism:
IL-13 Inhibition: By binding to IL-13, tralokinumab prevents it from interacting with its receptors, thereby reducing inflammation and other symptoms associated with atopic dermatitis.
Skin Barrier Improvement: Inhibiting IL-13 helps restore the skin's barrier function, reducing dryness and susceptibility to irritants.
Symptom Relief: Patients may experience reduced itching, redness, and skin lesions as the inflammatory response is mitigated.
ADTRALZA 150mg/ml Interactions ADTRALZA 150mg/ml
Vaccinations:
Live Vaccines: Avoid concurrent administration with live or live attenuated vaccines due to potential safety concerns.
Inactivated Vaccines: May be administered, but monitor for reduced efficacy.
Other Medications:
No significant interactions have been reported with other systemic immunosuppressants, but caution is advised.
Always inform your healthcare provider about all medications and supplements you are taking.
Dosage of ADTRALZA 150mg/ml
The dosage regimen of ADTRALZA 150 mg is designed to provide effective and sustained control of moderate to severe atopic dermatitis symptoms. Dosage should always be individualized by a healthcare professional based on patient response and tolerance.
- Initial Dose: Typically, a 150 mg dose is administered subcutaneously every two weeks.
- Maintenance Dose: After initial doses, the healthcare provider may adjust the interval or continue biweekly injections based on clinical improvement.
- Duration: Treatment duration varies depending on disease severity and response; long-term therapy may be required for chronic management.
- Administration: Given as a single 150 mg injection via the pre-filled syringe, ready for subcutaneous use.
- Missed Dose: If a scheduled dose is missed, it should be administered as soon as possible unless close to the next dose; avoid doubling up doses.
Patients should regularly follow up with their healthcare provider to monitor effectiveness and side effects, and to adjust dosage as needed for optimal disease control.
Possible side effects of ADTRALZA 150mg/ml
Like all medications, ADTRALZA may cause side effects, although not everyone experiences them. Awareness of potential adverse reactions helps with early recognition and management.
- Common Side Effects:
- Injection site reactions such as redness, swelling, pain, or itching.
- Upper respiratory tract infections including nasopharyngitis and sinusitis.
- Headache or mild fatigue.
- Uncommon Side Effects:
- Allergic reactions including rash or itching.
- Possible eye symptoms like conjunctivitis or keratitis reported in some cases.
- Serious Side Effects (Rare):
- Severe hypersensitivity or anaphylaxis requiring immediate medical attention.
- Signs of infection such as fever, chills, or persistent sore throat.
If you experience any severe or persistent side effects, contact your healthcare provider promptly. Regular monitoring during treatment helps ensure safety.
ADTRALZA 150mg/ml Contraindications ADTRALZA 150mg/ml
There are specific conditions and patient factors that contraindicate the use of ADTRALZA to avoid harm or complications.
- Known Hypersensitivity: History of allergic reactions to tralokinumab or any components of the formulation.
- Active Infections: Patients with severe infections should not initiate therapy until the infection resolves due to potential immune modulation.
- Immunocompromised Patients: Use with caution or avoid in patients with compromised immune systems unless benefits outweigh risks.
- Pediatric Use: Safety and efficacy have not been established in children under 18 years old.
- Pregnancy and Breastfeeding: Limited data available; consult a healthcare provider to weigh risks and benefits.
Always disclose your full medical history to your healthcare provider to determine if ADTRALZA is appropriate for you.
Storage of ADTRALZA 150mg/ml
Proper storage of ADTRALZA is essential to maintain its effectiveness and safety.
- Temperature: Store refrigerated between 2°C and 8°C (36°F to 46°F). Do not freeze.
- Light Protection: Keep the pre-filled syringes in their original packaging to protect from light exposure.
- Handling: Avoid shaking the syringe; handle gently.
- Room Temperature: Before injection, the syringe may be left at room temperature for up to 30 minutes to reduce injection discomfort.
- Disposal: Dispose of used syringes safely in sharps containers according to local regulations.
- Expiry: Do not use beyond the expiration date printed on the package.
Following these storage instructions ensures the medication maintains its potency and reduces risk of contamination or degradation.
ADTRALZA 150mg/ml features an exceptional active ingredient renowned for its potent effects, comprising Tralokinumab. This powerful formulation provides a superior solution for addressing diverse health concerns. With 150 mg/ml concentration and an easily manageable Solution for injection in pre-filled syringe, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about ADTRALZA 150mg/ml .
Welcome to Dwaey, specifically on ADTRALZA 150mg/ml page.
This medicine contains an important and useful components, as it consists of Tralokinumab.
ADTRALZA 150mg/ml is available in the market in concentration 150 mg/ml and in the form of Solution for injection in pre-filled syringe.
LEO PHARMA A/S is the producer of ADTRALZA 150mg/ml and it is imported from DENMARK,
The most popular alternatives of ADTRALZA 150mg/ml are listed downward .
-
Active Substance
-
Size
-
Indications
- No indications available.
-
Type
Solution for injection in pre-filled syringe
-
Company
Frequently Asked Questions
ADTRALZA 150mg/ml should be stored according to the instructions provided by LEO PHARMA A/S.
In general, it is recommended to store ADTRALZA 150mg/ml in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with ADTRALZA 150mg/ml may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking ADTRALZA 150mg/ml for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking ADTRALZA 150mg/ml . Some medications, including
ADTRALZA 150mg/ml , may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of ADTRALZA 150mg/ml , take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking ADTRALZA 150mg/ml without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking ADTRALZA 150mg/ml if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of ADTRALZA 150mg/ml during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 150 mg/ml,
and the specific recommendations of LEO PHARMA A/S.
The effects of ADTRALZA 150mg/ml on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 150 mg/ml, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking ADTRALZA 150mg/ml with or without food may vary depending on the medication
and the recommendations of LEO PHARMA A/S. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of ADTRALZA 150mg/ml in children or elderly individuals may depend on various factors, including
the specific medication, type Solution for injection in pre-filled syringe, and the recommendations of LEO PHARMA A/S. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of ADTRALZA 150mg/ml in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments